進階搜尋


  查詢北醫館藏
系統識別號 U0007-3007200823443400
論文名稱(中文) 合併給予輔酶Q10 與紅麴製品改善高膽固醇血症者血脂質與脂質氧化狀態之效應評估
論文名稱(英文) Effects of Monascus Rice Powder Co-supplemented with Coenzyme Q10 Improves Serum Lipids and Lipid Oxidative Status on Subjects with Hypercholesterolemia
校院名稱 臺北醫學大學
系所名稱(中) 保健營養學研究所
系所名稱(英) Graduate Institute of Nutrition and Health Sciences
學年度 96
學期 2
出版年 95
研究生(中文) 徐詩雯
研究生(英文) Shih-Wen Hsu
電子信箱 m507095012@tmu.edu.tw
學號 M507095012
學位類別 碩士
語文別 中文
口試日期 2008-06-16
論文頁數 94頁
口試委員 指導教授-黃士懿
委員-謝明哲
委員-謝榮鴻
委員-楊惠婷
委員-王銘富
中文關鍵字 高膽固醇血症  紅麴,輔酶  Q10  脂質過氧化  本體脂蛋白B 
英文關鍵字 hypercholesterolemia  Monascus  coenzyme Q10  lipid peroxidation  apolipoprotein B 
學科別分類
中文摘要 輔酶Q10 (Coenzyme Q10, CoQ10)的還原態—Ubiquinol (QH2)在週邊循環中,可當作抗氧化物質,與自由基作用變成氧化態(Ubiquinone, Q)。輔酶Q10 也參與維生素E 的再生、預防脂質過氧化。本實驗以高膽固醇血症患者為受試者,探討在長期合併攝取紅麴製品,是否影響血漿中輔酶Q10的濃度,並探討調節血脂之功效和可能機制;另外探討紅麴製品合併輔酶Q10,預防脂質氧化的功效。
實驗係以紅麴製品,給予高膽固醇血症者(24 人)連續攝取紅麴錠劑四個月(一天四顆,每顆含5 毫克monacolin K),每個月抽取血液評估其對血脂質、本體脂蛋白B 及抗氧化功能—輔酶Q10、維生素E、脂質過氧化物TBARS(Thiobarbituric acid reactive substances);另外招募高膽固醇血症者(37 人),分成三組,分別為紅麴組(M) (monacolins 12 毫克)、輔酶Q10 紅麴組(MQ)(monacolins 12 毫克加 CoQ10 30 毫克)及輔酶Q10 紅麴高劑量組(HMQ) (monacolins 24 毫克加CoQ10 60 毫克),參與調整期(2週)、實驗期(6週)及排空期(2週)三階段試驗。抽血檢驗分析膽固醇、血脂質與LDL-延遲反應(LDL lag time)。數據以mean ± SEM 表示,以Student’s t test 進行統計分析,當 p<0.05 代表有統計上的差異。
結果顯示,攝取紅麴製品4 個月後攝食前相比,其血清總膽固醇、低密度脂蛋白膽固醇、本體脂蛋白B 的濃度皆顯著下降,而高密度脂蛋白膽固醇濃度、血漿維生素E 濃度則無顯著差異;食用紅麴製品1 個月後與攝食前相比,其輔酶Q10 之濃度顯著下降。受試者在合併補充紅麴製品六週後,其血漿中MDA 濃度顯著下降,且LDL 氧化時間顯著延長,而添加輔酶Q10 的組別於排空期後,LDL 氧化延遲時間仍維持在其範圍中。
長期攝取紅麴製品,會藉由抑制HMG CoA reductase 活性與降低本體脂蛋白B 濃度,而降低血清總膽固醇與低密度脂蛋白膽固醇的濃度,同時MDA 濃度顯著降低;合併給予輔酶Q10 可延緩低密度脂蛋白之氧化,有助降低動脈粥狀硬化之發生或進展。
英文摘要 Recent studies showed a possibly interruption of monacolins, active compounds of Monascus rice powder, on coenzyme Q10 biosynthesis. Since the benefits of cholesterol-lowing effect on Monascus rice powder has been
revealed, the utilization of coenzyme Q10 still remains controversial. Thus, a clinical trial was conducted to investigate lipid-lowering and antioxidative effects of combined red yeast rice extract and coenzyme Q10 (CoQ10)
supplementation on hypercholesterolemic subjects.
24 subjects were recruited and supplemented by Monascus products for 4 months, which contained monacolin K 20mg. Blood samples were collected every months for lipids, apolipoprotein B, coenzyme Q10 and α-tocopherol determination. Forty subjects were recruited and were randomly divided into three groups such as Monascus rice powder 500 mg (M), equivalent to monacolins 12 mg; Monascus rice powder 500 mg plus CoQ10 30 mg (MQ), and Monascus rice powder 1 g plus CoQ10 60 mg (HMQ) by different doses supplementation. The supplementations administrated for 6 weeks, blood samples were collected every two weeks for cholesterol and low density lipoprotein (LDL) lag time, and TBARS(Thiobarbituric acid reactive substances) determination.
Results showed that the subjects had lower serum total cholesterol, LDL cholesterol, and apolipoprotein B concentration after four months of supplementation. Moreover, there were no alterations on high density lipoprotein (HDL) cholesterol level and α-tocopherol level. After one months supplementation, the concentration of plasma coenzyme Q10 significant decreased. In LDL-lag time, the data displayed a significant slower production
of conjugated dienes in all groups after six weeks of supplementation. However, in CoQ10 supplementing groups, the effect sustained after ceasing supplementation for two weeks. The concentration of plasma MDA level significant decreased in all groups after six weeks of supplementation.
The results confirmed the lipid-lowering effects of monacolins by inhibiting Hydroxymethyl glutaryl CoA reductase (HMG CoA reductase) activity and decreasing the concentration serum apolipoprotein B. Furthermore, addition of at least 30 mg CoQ10 could significantly enhance LDL antioxidative capacity in hypercholesterolemic subjects.
論文目次 中文摘要 ...................................................................................................................... i
英文摘要 .................................................................................................................... iii
致 謝 ..................................................................................................................... v
目 錄 .................................................................................................................... vii
圖目錄 ......................................................................................................................x
表目錄 ..................................................................................................................... xi
第一章、 緒 論 .......................................................................................................... 1
第二章、 文獻回顧 ...................................................................................................... 2
第一節、 高膽固醇血症 .................................................................................................. 2
一、 高膽固醇血症之盛行率 ...................................................................................... 2
二、 高膽固醇血症之生活型態的調整 ...................................................................... 2
三、 高膽固醇血症之藥物控制 .................................................................................. 3
四、 高膽固醇血症之飲食控制 .................................................................................. 3
五、 高膽固醇血症患者之膽固醇代謝 ...................................................................... 4
第二節、 紅麴 ......................................................................................................... 6
一、 紅麴簡介 .............................................................................................................. 6
二、 紅麴之活性成分及內生性膽固醇代謝 .............................................................. 6
第三節、 輔酶Q10 (Coenzyme Q10) .......................................................................... 8
一、 輔酶Q10 的代謝與生合成途徑 ........................................................................... 8
二、 輔酶Q10 與抗氧化功能 ....................................................................................... 9
三、 輔酶Q10 與粒線體功能 ..................................................................................... 10
第四節、 輔酶Q10 與紅麴的交互作用 ................................................................... 11
第三章、 實驗材料與方法 ......................................................................................... 12
第一節、 受試者招募與篩檢 ........................................................................................ 12
第二節、 實驗一:長期補充紅麴產品試驗 ................................................................ 13
一、 實驗設計 ............................................................................................................ 13
二、 樣本收集及處理 ................................................................................................ 14
三、 統計分析 ............................................................................................................ 25
viii
第三節、 實驗二:合併投予紅麴及輔酶Q10 產品試驗 ............................................. 26
一、 實驗設計 ............................................................................................................ 26
二、 樣本收集及處理 ................................................................................................ 26
三、 統計分析 ............................................................................................................ 29
第四章、 結 果 ........................................................................................................ 30
第一節、 實驗一:長期補充紅麴產品試驗 ................................................................ 30
一、 受試者之體位測量 ............................................................................................ 30
二、 受試者飲食紀錄 ................................................................................................ 30
三、 受試者對於紅麴製品之順應性(Compliance) ............................................. 30
四、 脂質代謝 ............................................................................................................ 31
(1) 血清總膽固醇、低密度脂蛋白膽固醇、本體脂蛋白B 濃度 ..................... 31
(2) 血清三酸甘油酯、高密度脂蛋白膽固醇濃度 ............................................. 32
五、 紅血球之脂肪酸組成 ........................................................................................ 32
六、 抗氧化功能 ........................................................................................................ 32
(1) 血漿輔酶Q10 濃度 .......................................................................................... 32
(2) 血漿及紅血球維生素E 濃度 ......................................................................... 33
(3) 血漿MDA 濃度 ............................................................................................... 33
七、 肝腎功能指標及其他生化分析 ........................................................................ 33
(1) 肝腎功能 ......................................................................................................... 33
(2) 心肌功能 ......................................................................................................... 33
第二節、 實驗二:合併投予紅麴及輔酶Q10 產品試驗 ............................................. 34
一、 受試者基本資料、體位測量 ............................................................................ 34
二、 受試者飲食紀錄 ................................................................................................ 34
三、 受試者對於紅麴製品之順應性(Compliance) ............................................. 34
四、 脂質代謝 ............................................................................................................ 35
(1) 血清總膽固醇、低密度脂蛋白膽固醇濃度 ................................................. 35
(2) 血清三酸甘油酯、高密度脂蛋白膽固醇濃度 ............................................. 35
五、 抗氧化功能 ........................................................................................................ 36
(1) 血漿MDA 濃度 ............................................................................................... 36
ix
(2) LDL 氧化延遲時間 ......................................................................................... 36
六、 肝腎功能指標 .................................................................................................... 36
第五章、 討 論 ......................................................................................................... 37
第一節、 長期攝取紅麴製品對於血脂質代謝之影響 ................................................ 37
一、 紅麴製品與血膽固醇 ........................................................................................ 37
二、 紅麴製品與血清本體脂蛋白B ......................................................................... 39
(1) 紅麴製品降低本體脂蛋白B 之生成與異化作用 ......................................... 39
(2) 紅麴製品降低本體脂蛋白B 之分泌 ............................................................. 40
(3) 本體脂蛋白B 與血清總膽固醇、低密度脂蛋白膽固醇濃度之相關性探討 .
......................................................................................................................... 41
三、 紅麴製品與三酸甘油酯及高密度脂蛋白膽固醇濃度 .................................... 43
(1) 紅麴製品對於三酸甘油酯濃度之影響 ......................................................... 43
(2) 紅麴製品對於高密度脂蛋白膽固醇濃度之影響 ......................................... 44
第二節、 紅麴製品與紅血球之脂肪酸組成 ................................................................ 45
第三節、 抗氧化功能之探討 ........................................................................................ 46
一、 補充紅麴製品與血漿中輔酶Q10 的濃度 ......................................................... 46
二、 補充紅麴製品對於血漿或紅血球維生素E 濃度之影響 ................................ 47
三、 補充紅麴製品及併用輔酶Q10 對於MDA 的影響 ........................................... 48
四、 併用輔酶Q10 與紅麴製品對於LDL 氧化延遲時間的影響 ............................. 50
第四節、 肝腎功能及其他生化數值之探討 ................................................................ 51
第六章、 結 論 .........................................................................................................52
參考資料 ................................................................................................................... 84
附 錄 ................................................................................................................... 89
A. 受試者同意書 ............................................................................................................ 89
B. 基本資料問卷 ............................................................................................................ 91
C. 三天飲食紀錄表 ........................................................................................................ 92
D. 人體(臨床)試驗計畫審核同意書 ............................................................................. 94
參考文獻 1. Stein EA. Management of dyslipidemia in the high-risk patient. Am Heart J 2002;144:S43-50.
2. Simons LA, Sullivan DR. Lipid-modifying drugs. Med J Aust 2005;182:286-9.
3. Faltaos DW, Urien S, Carreau V, et al. Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. Fundam Clin Pharmacol 2006;20:321-30.
4. Anderson JW. Diet first, then medication for hypercholesterolemia. Jama 2003;290:531-3.
5. Lin CC, Li TC, Lai MM. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol 2005;153:679-86.
6. Rader DJ, Hoeg JM, Brewer HB, Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994;120:1012-25.
7. Vega GL, Grundy SM. Hypercholesterolemia with cholesterol-enriched LDL and normal levels of LDL-apolipoprotein B. Effects of the step I diet and bile acid sequestrants on the cholesterol content of LDL. Arterioscler Thromb Vasc Biol 1996;16:517-22.
8. Innerarity TL, Weisgraber KH, Arnold KS, et al. Familial defective apolipoprotein B-100: Low density lipoproteins with abnormal receptor binding. Medical Sciences;84:6919-6923.
9. Chien KL, Hsu HC, Su TC, Chen MF, Lee YT, Hu FB. Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. J Lipid Res 2007;48:2499-505.
10. Sniderman A, Williams K, Haffner S, Sattar N. Insights from apoB: from better diagnosis & therapy to the Medusa Hypothesis. Atheroscler Suppl 2004;5:19-24.
11. Sacks FM. The apolipoprotein story. Atheroscler Suppl 2006;7:23-7.
12. Eisenbrand G. Toxicological evaluation of red mould rice. Mol Nutr Food Res 2006;50:322-7.
13. Cicero AF, Brancaleoni M, Laghi L, Donati F, Mino M. Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complement
Ther Med 2005;13:273-8.
14. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fonnebo V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 2006;1:4.
15. Nies LK, Cymbala AA, Kasten SL, Lamprecht DG, Olson KL. Complementary and alternative therapies for the management of dyslipidemia. Ann Pharmacother 2006;40:1984-92.
16. Li YG, Zhang F, Wang ZT, Hu ZB. Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. J Pharm Biomed Anal
2004;35:1101-12.
17. Monograph. Monascus purpureus (red yeast rice). Altern Med Rev 2004;9:208-10.
18. Lin YL, Wang TH, Lee MH, Su NW. Biologically active components and nutraceuticals in the Monascus-fermented rice: a review. Appl Microbiol Biotechnol 2008;77:965-73.
19. Choi JH, Ryu YW, Seo JH. Biotechnological production and applications of coenzyme Q10. Appl Microbiol Biotechnol 2005;68:9-15.
20. Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001;20:591-8.
21. Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 2006;40:445-53.
22. Oudshoorn JH, Lecluse AL, van den Berg R, Vaes WH, van der Laag J, Houwen RH. Decreased coenzyme Q10 concentration in plasma of children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2006;43:646-50.
23. Sohal RS, Kamzalov S, Sumien N, et al. Effect of coenzyme Q10 intake on endogenous coenzyme Q content, mitochondrial electron transport chain, antioxidative defenses, and life span of mice. Free Radic Biol Med
2006;40:480-7.
24. Belardinelli R, Mucaj A, Lacalaprice F, et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 2006;27:2675-81.
25. Yalcin A, Kilinc E, Sagcan A, Kultursay H. Coenzyme Q10 concentrations in coronary artery disease. Clin Biochem 2004;37:706-9.
26. Frei B, Kim MC, Ames BN. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci U S A 1990;87:4879-83.
27. L Ernster GD. Biochemical, physiological and medical aspects of ubiquinone unction. Biochim Biophys Acta. 1995;1271:195-204.
28. Lass A, Sohal RS. Effect of coenzyme Q(10) and alpha-tocopherol content of mtochondria on the production of superoxide anion radicals. Faseb J 2000;14:87-94.
29. Gutierrez J, Ballinger SW, Darley-Usmar VM, Landar A. Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells. Circ Res 2006;99:924-32.
30. Aguilaniu H, Durieux J, Dillin A. Metabolism, ubiquinone synthesis, and longevity. Genes Dev 2005;19:2399-406.
31. Guzman M, Cortes JP, Castro J. Effects of lovastatin on hepatic fatty acid metabolism. Lipids 1993;28:1087-93.
32. Loop RA, Anthony M, Willis RA, Folkers K. Effects of ethanol, lovastatin and coenzyme Q10 treatment on antioxidants and TBA reactive material in liver of
rats. Mol Aspects Med 1994;15 Suppl:s195-206.
33. de Bravo MG, Schinella G, Polo M, Tournier H. Effects of lovastatin on the fatty acid desaturation in a human lung mucoepidermoid carcinoma grown in nude mice. Biochem Mol Biol Int 1996;38:929-35.
34. Yang HT, Lin SH, Huang SY, Chou HJ. Acute administration of red yeast rice (Monascus purpureus) depletes tissue coenzyme Q(10) levels in ICR mice. Br J
Nutr 2005;93:131-5.
35. Huff MW, Telford DE, Edwards JY, et al. Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB. Arterioscler Thromb Vasc Biol 2002;22:1884-91.
36. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69:231-6.
37. Alberts AW, Chen J, Kuron G, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A 1980;77:3957-61.
38. Endo A, Hasumi K. Biochemical aspect of HMG CoA reductase inhibitors. Adv Enzyme Regul 1989;28:53-64.
39. Ostlund RE, Jr. Cholesterol absorption. Curr Opin Gastroenterol 2002;18:254-8.
40. Zhao SP, Liu L, Cheng YC, Li YL. Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with
coronary heart disease. Atherosclerosis 2003;168:375-80.
41. Chen L, Zhang J, Chan L. Apolipoprotein B synthesis: a square lattice model. J Lipid Res 1994;35:84-92.
42. Selby SL, Yao Z. Level of apolipoprotein B mRNA has an important effect of the synthesis and secretion of apolipoprotein B-containing lipoproteins. Studies
on transfected hepatoma cell lines expressing recombinant human apolipoprotein B. Arterioscler Thromb Vasc Biol 1995;15:1900-10.
43. Schaefer WH, Lawrence JW, Loughlin AF, et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 2004;194:10-23.
44. Katan MB, Zock PL, Mensink RP. Effects of fats and fatty acids on blood lipids in humans: an overview. Am J Clin Nutr 1994;60:1017S-1022S.
45. Hayes KC. Dietary fatty acids, cholesterol, and the lipoprotein profile. Br J Nutr 2000;84:397-9.
46. Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, Fisher EA. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 2004;113:1277-87.
47. Cazzola R, Rondanelli M, Russo-Volpe S, Ferrari E, Cestaro B. Decreased membrane fluidity and altered susceptibility to peroxidation and lipid composition in overweight and obese female erythrocytes. J Lipid Res
2004;45:1846-51.
48. Connor SL, Connor WE. Are fish oils beneficial in the prevention and treatment of coronary artery disease? Am J Clin Nutr 1997;66:1020S-1031S.
49. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res 1990;31:1149-72.
50. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A 1990;87:8931-4.
51. Levy HB, Kohlhaas HK. Considerations for supplementing with coenzyme Q10 during statin therapy. Ann Pharmacother 2006;40:290-4.
52. Bliznakov EG. More on the Chinese red-yeast-rice supplement and its cholesterol-lowering effect. Am J Clin Nutr 2000;71:152-4.
53. Kontush A, Hubner C, Finckh B, Kohlschutter A, Beisiegel U. Antioxidative activity of ubiquinol-10 at physiologic concentrations in human low density
lipoprotein. Biochim Biophys Acta 1995;1258:177-87.
54. Ernster L, Forsmark-Andree P. Ubiquinol: an endogenous antioxidant in aerobic organisms. Clin Investig 1993;71:S60-5.
55. Wei W, Li C, Wang Y, Su H, Zhu J, Kritchevsky D. Hypolipidemic and anti-atherogenic effects of long-term Cholestin (Monascus purpureus-fermented rice, red yeast rice) in cholesterol fed rabbits. J Nutr Biochem 2003;14:314-8.
56. Aniya Y, Yokomakura T, Yonamine M, et al. Screening of antioxidant action of various molds and protection of Monascus anka against experimentally induced liver injuries of rats. Gen Pharmacol 1999;32:225-31.
57. Hau MF, Smelt AH, Bindels AJ, et al. Effects of fish oil on oxidation resistance of VLDL in hypertriglyceridemic patients. Arterioscler Thromb Vasc Biol 1996;16:1197-202.
58. Palomaki A, Malminiemi K, Solakivi T, Malminiemi O. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. J Lipid Res 1998;39:1430-7.
59. Liu BH, Wu TS, Su MC, Chung CP, Yu FY. Evaluation of citrinin occurrence and cytotoxicity in Monascus fermentation products. J Agric Food Chem 2005;53:170-5.
論文全文使用權限
  • 同意授權瀏覽/列印電子全文服務,於2011-08-08起公開。


  • 若您有任何疑問,請與我們聯絡!
    臺北醫學大學 圖書館 簡莉婷
    E-mail:etds@tmu.edu.tw
    Tel:(02) 2736-1661 ext.2519
    Fax:(02) 2737-5446